Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
KBC Asset Management NV et al v. Aegerion Pharmaceuticals, Inc. et al
Case Number:
1:14-cv-10105
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Block & Leviton
- Fisher Potter
- Hogan Lovells
- Hutchings Barsamian
- Motley Rice
- Nutter McClennen
- Robbins Geller
- Ropes & Gray
Companies
Sectors & Industries:
-
December 07, 2017
Attys Get $4.5M Of $22M Aegerion Drug Marketing Settlement
A Massachusetts federal judge on Wednesday awarded $4.45 million in fees to attorneys who secured a $22.25 million settlement to end an investor class action accusing Aegerion Pharmaceuticals Inc. of hiding from shareholders the off-label marketing of the cholesterol drug Juxtapid.
-
December 05, 2016
Aegerion To Pay Investors $22M In Juxtapid Marketing Row
Aegerion Pharmaceuticals Inc. on Monday said it has agreed to pay $22.25 million to settle an investor class action in Massachusetts federal court alleging the biopharmaceutical company misled shareholders about off-label marketing of its flagship cholesterol drug Juxtapid.
-
January 16, 2014
Aegerion Hit With Shareholder Suit Over Juxtapid Labeling
Aegerion Pharmaceuticals Inc. was hit with a proposed class action in Massachusetts federal court Wednesday accusing the biopharmaceutical company of misleading shareholders about off-label marketing of its flagship cholesterol drug Juxtapid.